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Abstract
Background: Although sex differences have been reported for associations between components of metabolic
syndrome and inflammation, the question of whether there is an effect modification by sex in the association
between inflammation and metabolic syndrome has not been investigated in detail. Therefore, the aim of this
study was to compare associations of high sensitivity C-creative protein (hs-CRP) with metabolic syndrome and its
components between men and women.
Methods: A total of 1,305 subjects aged 40 years and over were recruited in 2004 in a metropolitan city in Taiwan.
The biochemical indices, such as hs-CRP, fasting glucose levels, lipid profiles, urinary albumin, urinary creatinine and
anthropometric indices, were measured. Metabolic syndrome was defined using the American Heart Association
and the National Heart, lung and Blood Institute (AHA/NHLBI) definition. The relationship between metabolic
syndrome and hs-CRP was examined using multivariate logistic regression analysis.
Results: After adjustment for age and lifestyle factors including smoking, and alcohol intake, elevated
concentrations of hs-CRP showed a stronger association with metabolic syndrome in women (odds ratio
comparing tertile extremes 4.80 [95% CI: 3.31-6.97]) than in men (2.30 [1.65-3.21]). The p value for the sex
interaction was 0.002. All components were more strongly associated with metabolic syndrome in women than in
men, and all sex interactions were significant except for hypertension.
Conclusions: Our data suggest that inflammatory processes may be of particular importance in the pathogenesis
of metabolic syndrome in women.
Background
The metabolic syndrome is a constellation of interre-
lated factors of metabolic origin including abdominal
obesity, high blood pressure, a low level of high-density
lipoprotein (HDL) cholesterol, a high triglyceride level,
and a high plasma glucose concentration [1-3]. The
etiology of this syndrome is largely unknown but pre-
sumably represents a complex interaction between
genetic, metabolic, and environmental factors [4,5]. Indi-
viduals with these characteristics commonly manifest a
prothrombotic and proinflammatory state, which is
associated with an increased risk for myocardial infarc-
tion, stroke and incident type 2 diabetes [6-18].
Although previous cross-sectional studies show that ele-
vated high sensitivity C-reactive protein (hs-CRP) levels
correlate significantly with features of the metabolic syn-
drome, including adiposity, hyperinsulinemia, insulin
resistance, hypertriglyceridemia, and low HDL choles-
terol [19,20], most of them examined the relationship
between hs-CRP and individual components of meta-
bolic syndrome. The previous study indicated that hs-
CRP levels were higher in women compared with men
and this gender difference was maintained across all eth-
nic subgroups [21]. In addition, sex differences have
been reported for associations between components of
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whether there is an effect modification by sex in the
association between inflammation and metabolic syn-
drome has not been investigated in detail. Therefore, in
this community-based cross-sectional study, we exam-
ined whether the relationship between hs-CRP and the
metabolic syndrome, defined by the American Heart
Association and the National Heart, Lung, and Blood
Institute (AHA/NHLBI, 2005) statement [22], is modi-
fied by gender, obesity, microalbuminuria, insulin resis-
tance, cardiovascular risk, and peripheral vascular
disease (PVD) in a Taiwanese population aged forty
years and over.
Methods
Participants
This was a community-based cross-sectional study based
on data from Taichung Community Health Study
(TCHS). A total of 2,359 residents aged 40 and over in
Taichung City, Taiwan, participated in October 2004. A
two-stage sampling design was used, with a sampling
rate proportional to size within each stage. At each
stage, simple random sampling was used. In the first
stage of sampling, the sampling unit was Li (administra-
tive units) and the selection probability for Li was set at
0.125. A total of 39 Lis were randomly selected from 8
city districts. In the second stage, 110 individuals were
randomly selected from each sample Li. A total of 4280
individuals were selected and 750 individuals who were
not eligible were excluded. A total of 3,530 subjects
were eligible, and 2,359 agreed to participate with an
overall response rate of 66.83%. The detailed methodol-
ogy has been described elsewhere [23-27]. Levels of hs-
CRP only were measured in the first 1305 subjects. This
study was approved by the Human Research Committee
of China Medical University Hospital. Written informed
consent was obtained from each participant.
Anthropometric measurement and laboratory
examination
Anthropometric measurements and blood samples were
obtained from the complete physical examination.
Weight and height were measured on an autoanthrop-
ometer (super-view, HW-666), with the subjects shoeless
and wearing light clothing. Body mass index (BMI) was
derived from the formula of weight (kg) ÷ (height)
2
(m
2). With the participant standing, waist circumference
was measured midway between the superior iliac crest
and the costal margin, and hip circumference at its
maximum protrusion point of the buttocks around the
pelvis, and then the waist-to-hip ratio (WHR) was calcu-
lated as a measure of regional fat distribution. Percent
body fat mass (%FM) was assessed by conventional tet-
rapolar bioelectrical impedance analysis using the Tanita
BC-418 MA Impedanciometer (Tanita Corp., Tokyo,
Japan) [28]. Blood pressure was measured by an electro-
n i cd e v i c e( C O L I N ,V P - 1 0 0 0 ,J a p a n )t h r e et i m e sa f t e r
the subjects were at rest for 20 minutes. The lowest sys-
tolic and diastolic blood pressure was recorded.
Blood was drawn from an antecubital vein in the
morning after a 12-hour overnight fasting and was sent
for analysis within four hours of blood collection. Bio-
chemical markers such as fasting plasma glucose, high-
density lipoprotein cholesterol (HDL-C), and triglyceride
were analyzed by a biochemical autoanalyzer (Beckman
Coluter Synchron system, Lx-20, Fullerton, CA, USA) at
the Clinical Laboratory Department of China Medical
University Hospital. Plasma cholesterol and triglyceride
levels were determined by an enzymatic colorimetric
method. The HDL-C level was measured by a direct
HDL-C method; HDL lipoprotein particles were solubi-
lized by a detergent to release HDL-C that reacted with
cholesterol esterase and cholesterol oxidase in the pre-
sence of chromogens to produce a colored product. The
low-density lipoprotein cholesterol (LDL-C) level was
measured by a direct LDL-C method, which used 2
kinds of detergents to solubilize the LDL particles. The
serum insulin level was measured by a commercial
enzyme-linked immunosorbent assay kit (Diagnostic
Products, Los Angeles, CA). The interassay coefficient
of variation (CV) for insulin was 8.7% and the intra-
assay CV was 3.4%. Insulin sensitivity was estimated
with a Homeostasis Model Assessment (HOMA-IR)
equation. The HOMA-IR equals fasting serum insulin
(μU/ml) times fasting plasma glucose (mmol/l) divided
by 22.5 [29]. Hs-CRP levels were measured by nephelo-
metry, a latex particle-enhanced immunoassay (TBA-
200FR, Tokyo, Japan). The interassay and intraassay
CVs were < 2.0% and < 1.9%, respectively. The lower
detection limit of the assay was 0.1 mg/l. Urinary creati-
nine (Jaffe’s kinetic method) and albumin (colorimetyl
bromcresol purple) were measured by an autoanalyzer
(Beckman Coluter Synchron system, Lx-20, Fullerton,
CA, USA). The interassay precision coefficient of varia-
tion was < 3.0% for both creatinine and albumin con-
centrations. The urinary albumin-to-creatinine ratio
(ACR) in the morning urine sample was used as a mar-
ker of the albumin excretion rate. Urinary ACR ranging
from 30 mg g-1 creatinine to 300 mg g-1 creatinine was
defined as microalbuminuria [30].
The measurement of brachial-ankle pulse wave velo-
city (baPWV) and the ankle-brachial index (ABI) were
determined using an automatic waveform analyzer (VP-
1000; Colin Co., Komaki, Japan) with well-documented
validity and reproducibility (coefficient of variation [CV]
= 3.31% and reproducibility coefficient = 0.947) [31].
Higher baPWV values indicated more severe arterial
stiffness. Lower ABI values indicated more severe PVD.
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cm/s, whereas an ABI index < 0.9 was considered the
presence of PVD [32].
Using the Framingham risk score based on the LDL-C
level [33], the estimated total coronary heart disease risk
over a 10-year period for every individual was calcu-
lated. Data on sociodemographic characteristics, includ-
ing gender, age, smoking, drinking, betel nut chewing
(the fourth most widely used addictive substance in the
world that were associated with metabolic syndrome,
chronic kidney disease, and heart disease [34-37]), family
history of cardiovascular-related diseases, physician-diag-
nosed diseases, and medication history were collected
when the participants underwent a complete physical
examination.
Definition of metabolic syndrome
The AHA/NHLBI statement was used to define the
metabolic syndrome, which had three or more of the
following abnormality: elevated waist circumference, ele-
vated triglycerides (≧150 mg/dL), reduced HDL-C (< 40
mg/dL for men, < 50 mg/dL for women), elevated blood
pressure (BP≧130/≧85 mmHg), and elevated fasting glu-
cose (≧100 mg/dL). Elevated waist circumference was
defined by Asia-Pacific cutoff limits: waist circumference
of 90 cm or more for men and 80 cm or more for
women because the importance of ethnic-specific cutoff
points for waist circumference [38]. As stipulated by the
definition we included all individuals receiving pharma-
cologic treatment for hypertension as having elevated
blood pressure, all subjects receiving fibrates as posses-
sing both elevated triglycerides and reduced HDL-C,
and all subjects previously diagnosed with type 2 dia-
betes as having elevated fasting glucose.
Statistical analysis
Continuous variables were reported as mean, whereas
categorical variables were reported as number (percen-
tage). Chi-square test was used to analyze the statistical
differences in cardiovascular risk factors between partici-
pants according to hs-CRP tertiles of gender. Since the
distribution of hs-CRP levels was skewed to the right,
natural log-transformation for CRP (ln hs-CRP) was
used to normalize the data. The comparisons of mean
values of ln hs-CRP (geometric means of hs-CRP)
according to the number of metabolic disorders were
performed by analysis of variance. Using a general linear
model, we tested the linear trends for increasing geo-
metric means of hs-CRP levels across the number of
MetS’s components. For ease of interpretation, geo-
metric means of un-transformed hs-CRP values and
their standard deviations were reported. Multiple logistic
regression analysis was used to investigate the effect of
hs-CRP as sex-specific tertiles on metabolic syndrome,
after adjusting for age, smoking, alcohol drinking, and
betel nut chewing status, an interaction of hs-CRP and
sex was further examined by adding the interaction
term into the full model. The cutoff points of hs-CRP
tertiles for males were 0.100 and 0.157, and for females
were 0.1 and 0.163, respectively. The high risk groups
for %FM and Framingham risk scores were determined
by the upper quartile of their distributions. All analysis
was conducted using SAS version 9.1 (SAS Institute Inc,
Cary, NC). Odds ratios and 95% confidence intervals
were calculated. A significant level of p < 0.05 was
reported.
Results
A total of 1291 subjects (625 men and 666 women)
were analyzed in the final model. The distributions of
cardiovascular risk factors according to groups of the
tertile for hs-CRP, stratified by gender, are shown in
Table 1. The mean values of BMI, waist circumference,
waist-to-hip ratio, fasting blood glucose, fasting insulin,
HOMA-IR, diastolic and systolic blood pressure, and %
FM significantly increased from the lowest tertile to the
highest tertile of hs-CRP in both sexes, but the mean
values of HDL-C decreased. The prevalence of arterial
stiffness, microalbuminuria, and high Framingham risk
score also significantly increased from the lowest tertile
to the highest tertile of hs-CRP in both sexes.
Fig 1 shows the geometric means of hs-CRP by the
number of components of the metabolic syndrome.
There was a linear increase in geometric means of hs-
CRP with the increasing number of components of the
metabolic syndrome in both sexes (P for trend < 0.001
for both men and women). CRP levels with 0-3 compo-
nents of MS are similar in men and women but are raised
more with each additional MS component in women
compared to men (p = 0.018 for sex interaction).
After adjusting for age, smoking status, alcohol drink-
ing, and betel nut chewing, hs-CRP was associated with
the metabolic syndrome defined by AHA/NHLBI and all
its components’ abnormalities (Table 2). The ORs for
women were greater than those for men. In men, the
OR of the middle tertile compared to the lowest tertile
was significant only for abdominal obesity. The ORs of
upper tertile were significant for all components of
metabolic syndrome except for low HDL-C. In women,
the ORs of middle tertile were significant for hypertri-
glyceridemia, abdominal obesity, and low HDL-C and
those for the upper tertile were significant for all com-
ponents. In both sexes, the linear trend was statistically
significant for metabolic syndrome and all its compo-
nents except for low HDL-C in men. After either
excluding those ind i v i d u a l sw i t hd i a b e t e sa n df i b r a t e
users or focusing on nonsmokers, similar findings were
found. Sex interactions were significant for metabolic
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(p = 0.002 for sex*metabolic syndrome; p = 0.049 for
sex*hyperglycemia; p = 0.004 for sex*hypertriglyceride-
mia; p < 0.001 for sex*abdominal obesity; and p = 0.017
for sex*low HDL-C).
Table 3 shows the adjusted ORs of metabolic syndrome
associated with a 1-SD increase in ln hs-CRP stratified by
the status of insulin resistance, obesity, microalbuminuria,
cardiovascular risk, and arteriosclerosis for men and
women in order to examine the gender difference in the
association of metabolic syndrome with hs-CRP according
to the status of the above cardiovascular factors. The gen-
der difference still remains the same: adjusted ORs slightly
larger in females than in males and more ORs for females
than for males reached statistical significance. Due to
s m a l ls a m p l es i z ei ns o m es u b groups, some interactions
were not statistically significant.
Discussion
The findings in this population-based study showed that
Taiwanese individuals with elevated hs-CRP levels, pre-
dominantly within the reference range, had a signifi-
cantly increased likelihood of having the metabolic
syndrome in men and women, independent of their age,
smoking, alcohol drinking and betel nut chewing (Table
2). However, associations were considerably stronger in
Table 1 The distributions of cardiovascular risk factors according to groups of the tertile for hs-CRP, stratified by
gender
Variables Mean (SD)
Men (N = 625) Women (N = 666)
Lower
tertile
≦0.1 mg/l
(N = 299)
Middle tertile
0.1-0.157
mg/l
(N = 123)
Upper tertile
> 0.157
mg/l
(N = 203)
P
value
Lower
tertile
≦0.1 mg/l
(N = 330)
Middle tertile
0.1-0.163 mg/l
(N = 115)
Upper tertile
> 0.163
mg/l
(N = 221)
P
value
Age (years) 56.8 (11.6) 57.5 (12.4) 59.0 (13.0) 0.15 52.2 (9.4) 55.8 (10.8) 56.7 (9.7) < .001
Body mass index (kg/m
2) 24.4 (2.9) 25.4 (3.3) 25.3 (3.2) < .001 22.6 (2.5) 24.4 (3.2) 25.3 (3.7) < .001
Smoking (%)
† 74 (24.8) 31 (25.2) 70 (34.5) 0.04 12 (3.7) 1 (0.9) 10 (4.5) 0.21
Drinking (%)
† 120 (40.1) 55 (44.7) 66 (32.5) 0.07 46 (14.0) 7 (6.1) 19 (8.6) 0.03
Betel nut chewing (%)
† 14 (4.7) 12 (9.8) 13 (6.5) 0.15 1 (0.3) 0 (0.0) 0 (0.0) 0.60
Exercise (%)
† 201 (67.5) 85 (69.1) 131 (64.5) 0.66 224 (67.9) 77 (67.0) 136 (61.5) 0.29
Waist circumference (cm) 85.1 (8.2) 88.2 (7.8) 88.3 (9.1) < .001 73.6 (6.5) 78.3 (8.1) 81.3 (9.6) < .001
Waist-to-hip ratio 0.9 (0.1) 0.90 (0.1) 0.90 (0.1) 0.004 0.79 (0.1) 0.82 (0.1) 0.83 (0.1) < .001
Fasting blood glucose (mg/dl) 102.8 (24.2) 103.5 (22.4) 111.3 (33.5) 0.002 96.52 (21.3) 99.2 (18.1) 109.1 (37.1) < .001
Fasting insulin (uU/ml) 8.1 (6.1) 9.5 (7.0) 10.0 (7.4) 0.005 6.5 (5.7) 8.1 (7.3) 10.1 (7.4) < .001
HOMA-IR 2.1 (1.9) 2.5 (2.2) 2.8 (2.3) 0.001 1.6 (1.8) 2.1 (2.3) 2.9 (2.8) < .001
Total cholesterol (mg/dl) 202.6 (35.3) 201.2 (37.7) 204.5 (39.7) 0.73 205.0 (40.0) 214.0 (33.5) 207.4 (37.5) 0.10
Triglyceride (mg/dl) 121.2 (105.1) 143.9 (41.2) 139.1 (74.2) 0.05 84.3 (45.3) 107.7 (53.4) 127.2 (88.7) < .001
HDL-cholesterol (mg/dl) 42.7 (11.7) 41.2 (11.1) 39.9 (9.6) 0.02 53.7 (14.0) 50.4 (12.9) 46.6 (10.8) < .001
LDL-cholesterol (mg/dl) 129.4 (31.7) 127.0 (33.9) 133.5 (36.3) 0.20 125.3 (34.8) 134.6 (27.8) 129.9 (36.2) 0.03
Diastolic blood pressure (mmHg) 80.2 (10.4) 83.0 (10.4) 83.4 (11.3) 0.002 72.7 (11.2) 76.3 (13.6) 77.8 (11.6) < .001
Systolic blood pressure (mmHg) 133.2 (19.1) 138.1 (19.1) 140.6 (19.9) < .001 125.6 (18.6) 134.1 (22.7) 136.8 (22.2) < .001
Family history of diabetes (%)
† 80 (26.8) 29 (23.6) 47 (23.3) 0.62 93 (28.2) 19 (16.5) 59 (26.7) 0.04
Diabetes (%)
† 35 (11.7) 12 (10.2) 43 (20.7) 0.006 17 (5.2) 14 (11.6) 41 (19.1) < 0.001
Antidiabetes medication (%)
† 26 (8.7) 5 (4.2) 30 (14.4) 0.031 12 (3.6) 5 (4.1) 26 (12.1) < 0.001
Antihypertension medication (%)
† 47 (16.0) 31 (27.0) 61 (29.6) < 0.001 39 (12.0) 26 (21.9) 58 (27.2) < 0.001
Antihyperlipid medication (%)
† 17 (5.9) 8 (7.0) 22 (10.8) 0.126 11 (3.4) 6 (5.1) 13 (6.2) 0.296
Metabolic syndrome (%)
† 106 (35.5) 51 (43.2) 116 (55.8) < 0.001 56 (17.0) 55 (45.5) 112 (52.1) < 0.001
Arterial stiffness
† 16 (5.4) 6 (4.9) 15 (7.4) 0.55 24 (7.3) 7 (6.1) 18 (8.1) 0.79
PVD
† 198 (67.1) 85 (65.1) 165 (86.8) 0.001 155 (47.4) 68 (59.1) 155 (71.1) < .001
Microalbuminuria (ACR≧30 μg/
min)
†
45 (15.1) 21 (17.1) 52 (25.6) 0.01 52 (15.8) 36 (31.3) 68 (31.2) < .001
High Framingham risk factors (%)
† 76 (25.4) 37 (30.1) 79 (43.8) < .001 79 (23.9) 45 (39.1) 117 (52.9) < .001
%body fat mass 25.1 (5.0) 27.1 (5.8) 28.1 (5.5) < .001 34.2 (5.2) 37.8 (4.9) 39.1 (5.9) < .001
Homeostasis model assessment of insulin resistance (HOMA-IR), high-density lipoprotein (HDL), low-density lipoprotein (LDL), albumin-creatinine ratio (ACR),
ankle-brachial index (ABI), brachial-ankle pulse wave velocity (baPWV), highly sensitive C-reactive protein (hs-CRP), peripheral vascular disease (PVD): ankle-
brachial index (ABI) < 0.9; arterial stiffness: brachial-ankle pulse wave velocity (baPWV) > 1400 cm/s; Framingham risk factors
33,
†: n (%)
Lai et al. BMC Public Health 2010, 10:429
http://www.biomedcentral.com/1471-2458/10/429
Page 4 of 8w o m e nt h a ni nm e n .I na d d i t i o n ,t h er e s u l t ss h o w e d
that hs-CRP was a significant risk factor of metabolic
syndrome’s components with a stronger association in
women. We also found significant gender difference in
the association of metabolic syndrome with hs-CRP
after stratification according to the status of insulin
resistance, obesity, microalbuminuria, cardiovascular
risk, and arteriosclerosis (Table 3).
Despite evidence indicating that inflammation is
related to metabolic syndrome [20,39], data from
epidemiologic studies are sparse. Yudkin et al. examined
relationships between levels of hs-CRP and components
of metabolic syndrome such as obesity, blood pressure,
dyslipidemia and insulin resistance in a group of 107
healthy persons [20]. However, their study focused on
exploring the mechanisms underlying the relationship of
inflammatory process and coronary heart disease and
their finding require further testing in both epidemiolo-
gical and clinical studies with larger sample size. In
Laaksonen’s study, they examined the association
between CRP levels and the development of the meta-
bolic syndrome and diabetes in 680 men with 11 years
of follow-up [39]. In Ridker work, although the relation-
ship of hs-CRP with components of the metabolic syn-
drome was examined in a large-scale population [40],
their study subjects restricted to healthy women, who
participating in an ongoing trial of aspirin and vitamin E
for primary prevention. Therefore both studies cannot
examine the interaction of sex and CRP.
There were two studies examining the association
between CRP and metabolic syndrome in Chinese
[41,42]. Both of these two studies measuring CRP, not
hs-CRP, thus they could not detect CRP levels less than
0.25 mg/L. The median value of CRP in our study was
more close to that reported by Chien’se ta la n dm u c h
lower than that by Ye et al. Chien’s study adopted both
the updated WHO and NCEP-ATPIII definition of
metabolic syndrome for Asian Americans and Ye’s study
adopted the NCEP-ATPIII definition while we adopted
AHA/NHLBI one. Both of them identified significant
association between CRP and metabolic syndrome and/
or its components, but they did not examine whether
there existed gender difference in this association.
There were limited studies examining whether there
exists a sex difference in the association between a
proinflammatory state and metabolic syndrome [43].
Our observation that hs-CRP is more strongly associated
with metabolic syndrome in women than in men is in
line with results of Ahonen’ss t u d y[ 4 3 ] ,w h i c hi n c l u d e d
subjects with elevated blood pressure. In addition, their
results showed there was no gender difference in the
level of hs-CRP in individuals without metabolic syn-
drome, but the level of hs-CRP was significantly lower
in men with metabolic syndrome than in women with
metabolic syndrome. In a study observing no gender dif-
ference in CRP level [42], an association between CRP
and metabolic syndrome had been reported as a whole
and gender difference in the association between CRP
and metabolic syndrome had not been explored.
Hs-CRP was an easily measured inflammatory biomar-
ker and has several direct effects at the level of the ves-
sel wall [44]. It has been shown hs-CRP has associations
with endothelial dysfunction and insulin resistance syn-
drome [20]. Our finding showed that sex difference in
Figure 1 Figure 1 Geometric means of Hs-CRP and 95% CI
according to the number of abnormal components of the
metabolic syndrome, defined by criteria of the American Heart
Association/National Heart, Lung, and Blood Institute (AHA/
NHLBI) according to gender.
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m i g h ts u g g e s tt h a th o r m o n em i g h tp l a yar o l eo nt h e
inflammatory mechanism. Whether sex hormone is
responsible for the association of metabolic syndrome
with hs-CRP needs to be explored.
Limitations of this study must be considered. The
principal limitation relevant to the interpretation of our
results is the use of cross-sectional data; thus, causal
pathways underlying the observed relationships cannot
be inferred. Second, these analyses were restricted to the
first 1305 subjects entering the current study, thus
potential selection bias might exist. To assess this possi-
bility, we examined the demographic characteristics of
the individuals with and without hs-CRP measurement
by comparing age, sex, and administrative unit, and
similar distributions were found. The non-differential
distributions in age, sex, and administrative unit, indi-
cate this kind of selection error might be random, thus,
t h er e s u l t sc o u l db eb i a s e dt o w a r dt h en u l l ,al e s s e r
threat to validity.
This finding would have implications for prevention.
AHA/NHLBI metabolic syndrome definition, an update
of the NCEP ATP III, has the primary purpose for diag-
nosing the persons with metabolic syndrome for lifestyle
therapies to reduce long-term risk of developing cardio-
vascular disease and type 2 diabetes mellitus. This issue
has become more important since recent reports have
suggested prevention/delay of diabetes with lifestyle
intervention [45,46]. Thus, the stronger association
between hs-CRP and metabolic syndrome by AHA/
NHLBI definition in females indicates that lifestyle inter-
ventions should aim at female subpopulation with meta-
bolic syndrome who will have a higher likelihood of
development of diabetes and cardiovascular events.
In summary, the study demonstrates that elevated
concentrations of hs-CRP showed a stronger association
with metabolic syndrome in women than in men. This
finding suggests that chronic inflammation may be of
particular importance in the pathogenesis of metabolic
syndrome in women. Our study finding has important
implication on screening of metabolic syndrome.
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Table 2 The adjusted odds ratios (ORs) of having metabolic syndrome and abnormalities of its components for tertiles
of hs-CRP
Variables Adjusted OR (95% CI)
a
Men P for Women P for
Middle tertile
(0.1-0.157 mg/l)
Upper tertile
(> 0.157 mg/l)
trend Middle tertile
(0.1-0.163 mg/l)
Upper tertile
(> 0.163 mg/l)
trend
Metabolic Syndrome (AHA/NHLBI) 1.60 (1.11-2.31) 2.30 (1.65-3.21) < .0001 3.52 (2.28-5.42) 4.80 (3.31-6.97) < .0001
Hyperglycemia 0.97 (0.67-1.41) 1.46 (1.05-2.04) 0.03 1.37 (0.91-2.07) 1.81 (1.28-2.55) 0.0008
Hypertriglyceridemia 1.44 (0.97-2.12) 1.93 (1.36-2.74) 0.0002 2.00 (1.22-3.29) 3.58 (2.38-5.39) < .0001
Hypertension (%)
† 1.19 (0.80-1.77) 1.77 (1.22-2.57) 0.003 1.06 (0.70-1.60) 2.00 (1.41-2.83) 0.0001
Abdominal obesity (%)
† 1.50 (1.00-2.23) 1.89 (1.32-2.69) 0.0004 3.26 (2.10-5.06) 4.99 (3.41-7.29) < .0001
Low HDL cholesterol 1.38 (0.96-1.99) 1.39 (1.00-1.94) 0.04 1.54 (1.07-2.23) 2.39 (1.73-3.30) < .0001
aLogistic regression adjusting for age, smoking, alcohol drinking and betel nut chewing.
American Heart Association and National Heart Lung and Blood Institute (AHA/NHLBI)
Table 3 The ORs of MetS associated with a 1-SD increase
in ln hs-CRP stratified by the status of obesity,
microalbuminuria, insulin resistance, cardiovascular risk,
and arteriosclerosis for men and women
P for interaction
of sex and hs-CRP
Adjusted OR
(95% CI)
a
Variables Men Women
Insulin resistance (HOMA-IR≧2.53)
No 0.031 1.29 (1.07-1.55)** 1.19 (0.96-1.47)
Yes 0.057 1.26 (0.98-1.65) 1.93 (1.40-2.78)***
Insulin resistance (insulin≧10.40 μU/ml)
No 0.081 1.26 (1.04-1.52)* 1.40 (1.11-1.76)**
Yes 0.043 1.26 (0.94-1.75) 1.57 (1.09-2.34)*
High % fat mass
No 0.073 1.26 (1.07-1.49)** 1.35 (1.10-1.65)**
Yes 0.026 1.10 (0.78-1.60) 1.58 (1.15-2.25)**
Microalbuminuria (ACR≧30 μg/min)
No 0.072 1.28 (1.08-1.53)** 1.48 (1.21-1.81)***
Yes 0.043 1.29 (0.99-1.72) 1.83 (1.35-2.58)***
High Framingham risk factors
No 0.042 1.24 (1.03-1.50)* 1.39 (1.12-1.73)**
Yes 0.053 1.33 (1.05-1.72)* 1.82 (1.35-2.54)***
Arterial stiffness
No 0.115 1.21 (0.84-1.71) 1.51 (1.07-2.12)*
Yes 0.034 1.27 (1.09-1.50)** 1.58 (1.29-1.95)***
aLogistic regression adjusting for age, smoking, alcohol drinking and betel
chewing.
Framingham risk factors
33
*:p < 0.05; **:p < 0.01; ***:p < 0.001.
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